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To determine whether attenuated simian immunodeficiency virus (SIV) vaccines confer protection against superinfection
via secondary cellular immune responses, we searched for markers of immune activation following rechallenge. Productive
infection with either attenuated SIVmacC8 or wild-type SIVmacJ5 resulted in a transient increase in T-lymphocyte CD25 and
Mafa-DR expression. A pronounced increase in the frequency of FAS CD8 lymphocytes was observed following SIVmacJ5
infection only. A transient increase in lymphocytes positive for intracellular IFN- and IL-4 was observed following primary
infection with either virus. In contrast, lymphocytes positive for intracellular IL-2 were reduced. Following SIVmacJ5 challenge
of SIVmacC8-infected vaccinees, no evidence of detectable superinfection was obtained. Rechallenge of vaccinees did not
alter the frequency of activated peripheral T-lymphocytes, perturb cytokine profiles, or generate an anamnestic antibodyINTRODUCTION
Simian immunodeficiency virus (SIV) is closely related
to human immunodeficiency virus (HIV) in its genomic
organization (Chakrabarti et al., 1987; Franchini et al.,
1987; Hirsch et al., 1987), its pathogenicity (Daniel et al.,
1985; Letvin, 1990), and its use of CD4 and chemokine
receptors to infect target cells (Deng et al., 1997; Hill et
al., 1997). Infection of macaques with wild-type SIV is
characterized by persistent infection, gradual erosion of
immune function, loss of CD4 cells in susceptible ani-
mals, and fatal opportunistic infections similar to those
observed with HIV infection of humans (Kestler et al.,
1990; Letvin et al., 1985; Sharma et al., 1992). Conse-
quently, this animal model is widely used to study the
clinical progression to immunodeficiency (Lu et al., 1998;
Zink et al., 1998), mechanisms of pathogenesis (Hodge et
al., 1998), and the efficacy and safety of vaccines (Al-
mond and Heeney, 1998) and drugs against HIV (Tsai et
al., 1995; Wyand, 1992).
At present, the most potent protection observed using
the SIV model has been achieved through immunization
with live attenuated virus (Almond et al., 1995; Daniel et
al., 1992; Desrosiers, 1990; Lohman et al., 1994; Stahl-
Hennig et al., 1996; Wyand et al., 1996). Inoculation of
juvenile macaques with live attenuated SIV generates a
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338low-level infection that renders recipients resistant to
subsequent superinfection with pathogenic wild-type SIV
(Connor et al., 1998; Cranage et al., 1997; Nilsson et al.,
1998; Rud et al., 1994a). Unfortunately, attenuated SIV
demonstrates a propensity for repairing attenuating de-
letions in vivo (Carl et al., 1999; Sawai et al., 2000;
Whatmore et al., 1995) and infection of infant or suscep-
tible adult macaques with attenuated SIV can cause
disease (Baba et al., 1995, 1999; Ruprecht et al., 1996).
Consequently, it is unlikely that an attenuated HIV vac-
cine will ever be utilized in clinical trials. Nevertheless, if
the mechanism of vaccine protection were understood,
then it may be possible to reproduce it by less hazardous
means. Yet, it still remains to be established if protection
is mediated by immunological responses or through viral
interference (Rud et al., 1994b). To date, passive transfer
of immune sera and lymphocyte depletion experiments
have yet to establish a role for serological or cell-medi-
ated responses alone in vaccine-induced protection (Al-
mond et al., 1997; Stebbings et al., 1998). In order to
establish a role for any combination of immune re-
sponses in vaccine-mediated control of superinfection,
we established assays to measure lymphocyte activation
and cytokine production. These assays were used to
characterize primary cellular immune responses follow-
ing infection with attenuated and wild-type SIV and thenresponse. These data do not support the hypothesis that
induction of vigorous T-cell responses upon rechallenge.
To whom correspondence and reprint requests should be ad-
dressed. Fax: 44 (0) 1707 650223. E-mail: rstebbings@nibsc.ac.uk.
doi:10.1006/viro.2002.1379
0042-6822/02 $35.00tion conferred by live attenuated SIV is mediated by the
Elsevier Science (USA)
to look for secondary cellular immune responses follow-
ing rechallenge of vaccinees with wild-type SIV. Anyprotec
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recall of previously observed cellular immune responses
could then be attributed to superinfection resistance.
RESULTS
Infection with wild-type SIVmacJ5 and attenuated
SIVmacC8
Following challenge of group A (R33 through R36) with
SIVmacJ5 and group B (R37 through R40) with SIVmacC8
at day 0, all eight animals were positive by DNA PCR for
SIV gag by day 58 (Table 1). At this time virus could be
reisolated from the peripheral blood mononuclear cells
(PBMC) of three SIVmacJ5 animals (R33, R34, and R36)
but from only one SIVmacC8 animal (R40). All eight ani-
mals were positive for SIV vRNA at day 15 but all sam-
ples were below the detection limit of the assay on days
58 and 113 (Table 1). Mean log SIV RNA copies per
milliliter of plasma from SIVmacJ5 challenged animals
were significantly higher than those for SIVmacC8 chal-
lenged animals (5.3  0.12 and 3.5  0.59, respectively),
by unpaired t test (P  0.001, Table 1). Following re-
challenge of SIVmacC8 animals with SIVmacJ5 on day
218, no full-length SIVmacJ5 nef proviral DNA could be
detected in PBMC. In contrast, all new naive controls
R265 through 268 (group C) challenged contemporane-
ously were positive by virus isolation, SIV gag polymer-
ase chain reaction (PCR), and J5 nef PCR. At 15 days post
SIVmacJ5 challenge there was no significant difference
between the mean DNA loads for group A and group C
(4875  3464 copies/106 PBMC and 3586  4492 cop-
ies/106 PBMC, respectively), by unpaired t test (P 
0.666).
All eight macaques challenged with SIVmacJ5 or SIV-
macC8 seroconverted to SIVgp140 by day 15 and SIVp27
by day 58 (Figs. 1A and 1B; individual data not shown).
Neutralizing antibody activity against SIVmacJ5 was first
detected in macaques R35, R37, and R38 at day 58.
Neutralizing antibody activity was detected in all eight
animals by day 113 (Fig. 1C; individual data not shown).
At day 113 anti-SIVgp140 end-point titers of SIVmacJ5
animals were significantly higher than those of SIV-
macC8 animals, by unpaired t test (P  0.042). Mean
anti-SIVp27 titers for the sum of days 58, 113, 218, and
274 were significantly higher for SIVmacJ5 than SIV-
macC8 animals, by unpaired t test (P  0.026), but not
at single time points. By day 218 mean neutralizing anti-
body titers were significantly higher in SIVmacJ5 than
SIVmacC8 animals, by unpaired t test (P  0.026). No
anamnestic anti-SIVgp140, anti-SIVp27, or neutralizing
antibody response was detected in SIVmacC8 animals
following rechallenge with SIVmacJ5. Contemporane-
ously challenged naive controls, R265 through R268,
seroconverted to SIVgp140 and SIVp27 by day 274.
Apart from macaque R268, the proportion of CD4
PBMC in groups A, B, and C remained within reference
range following SIV challenge (Figs. 2A–2C). The propor-
tion of CD8 PBMC in groups A, B, and C exhibited a
transient increase above reference range at 15 days after
TABLE 1
Virus Detection on Indicated Days Postchallenge with SIVmacJ5 or SIVmacC8a
Animal
Days post SIV challenge
0 15 58 113 218(0) 233(15) 274(56) 378(160)
PCR Virus PCR vRNA PCR Virus PCR Virus PCR Virus PCR Virus PCR Virus PCR Virus
R33    5.42    
R34    5.29    
R35    5.14    
R36    5.35    
R37    4.23     nd nd  (C8)   (C8)   (C8) 
R38    3.46     nd nd    (C8)   (C8) 
R39    2.78     nd nd  (C8)   (C8)   
R40    3.51     nd nd  (C8)   (C8)   
R265    (J5)   (J5)   (J5) 
R266    (J5)   (J5)   (J5) 
R267    (J5)   (J5)   (J5) 
R268    (J5)   (J5)   (J5) 
Challenge SIV J5/C8 SIV J5
a Shown is virus detected on indicated days post SIV challenge. On day 0 macaques R33–R36 were challenged with SIVmacJ5 and macaques
R37–R40 with SIVmacC8. On day 218 macaques R37–R40 and R265–R268 were challenged with SIVmacJ5. Under PCR a plus sign indicates that SIV
gag proviral DNA was detected. Under PCR a minus sign indicates that no SIV proviral DNA was detected. Under PCR, (C8) or (J5) indicates that the
nef proviral DNA detected was from SIVmacC8 or SIVmacJ5, respectively. Figures under vRNA for day 15 refer to mean log SIV RNA copies per milliliter
of plasma. All samples for days 58 and 113 were below the cut-off for the assay: 2.3 log SIV RNA copies per milliliter of plasma. Under Virus a plus
sign indicates that cell-associated virus was recovered from 5  106 PBMC and a minus sign indicates that no virus was recovered from 5  106
PBMC. nd indicates that results were not determined.
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challenge (Figs. 3A–3C). Following rechallenge of SIV-
macC8 animals with SIVmacJ5 on day 218, no transient
increase in CD8 PBMC was observed.
T-lymphocyte activation following SIV challenge
Following primary challenge with either SIVmacJ5 or
SIVmacC8 a transient increase in the proportion of
CD3 CD25 lymphocytes was observed (Figs. 4A–
4C). At 4 weeks postchallenge the proportion of CD3
CD25 lymphocytes was significantly above reference
range in groups A, B, and C, by paired t test (P 
0.023, P  0.004, and P  0.012, respectively). No
significant increase in the proportion of group B CD3
CD25 lymphocytes was detected following rechal-
lenge with SIVmacJ5. Similar data were obtained with
the proportion of CD3 PBMC expressing Mafa-DR,
which cross-reacted with anti-HLA-DR antibodies
(data not shown).
Following challenge of group A with SIVmacJ5 the
proportion of CD8 FAS lymphocytes (Fig. 5A) in-
creased significantly above reference range at day 29, by
paired t test (P  0.016), remaining elevated until day
169. For group B challenged with SIVmacC8 the propor-
tion of CD8 FAS lymphocytes (Fig. 5B) was signifi-
cantly above reference range only at day 85, by paired t
test (P  0.003). Following SIVmacJ5 challenge of group
C the proportion of CD8 FAS lymphocytes (Fig. 5C)
increased significantly above reference range at day 233,
FIG. 1. Antibody responses to challenge of group A (R33–R36) with wild-type SIVmacJ5 on day 0, group B (R37–R40) with attenuated SIVmacC8 on
day 0, and groups A and C (R265–R268) with wild-type SIVmacJ5 on day 218. (A) Log anti-SIV gp140 end-point titers. (B) Log anti-SIV p27 end-point
titers. (C) Log anti-SIV neutralizing antibody titers.
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by paired t test (P  0.004). No significant increase in
CD8 FAS lymphocytes was detected in SIVmacC8 an-
imals following rechallenge with SIVmacJ5. No signifi-
cant change in the proportion of FAS CD4 cells in
groups A, B, or C was observed following SIV challenge
(data not shown).
Cytokine expression by lymphocytes following SIV
challenge
Mitogen stimulation either had no effect or decreased
the numbers of IL-4 CD3 lymphocytes before and after
SIV challenge (data not shown). Only the data for un-
FIG. 2. Changes in the proportion of CD4 PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type SIVmacJ5
on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5C on day 218.
(C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal reference range
based on 2 standard deviations  mean proportion of CD4 PBMC derived from two prebleeds of each animal used in this study.
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stimulated IL-4 secretion are reported here. Following
challenge of group A with SIVmacJ5 and group B with
SIVmacC8, the proportion of IL-4 CD3 lymphocytes
(Figs. 6A and 6B) increased significantly above reference
range at days 85 and 113, respectively, by paired t test
(P  0.009 and P  0.049, respectively). At day 113 the
FIG. 3. Changes in the proportion of CD8 PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type SIVmacJ5
on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5 on day 218.
(C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal reference range
based on 2 standard deviations  mean proportion of CD8 PBMC derived from two prebleeds of each animal used in this study.
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mean proportion of group A IL-4 CD3 lymphocytes
was significantly greater than that of group B, by un-
paired t test (P  0.006). No significant increase in the
proportion of group B IL-4 CD3 lymphocytes was de-
tected following rechallenge with SIVmacJ5. In contrast,
contemporaneous challenge of group C with SIVmacJ5
resulted in a significant increase in the proportion of
IL-4 CD3 lymphocytes (Fig. 6C) to above reference
range at day 233, by paired t test (P  0.049).
For detection of IFN- or IL-2 cells only the data
following mitogen stimulation are shown here. No IFN-
or IL-2 cells were detected in the absence of mitogen
FIG. 4. Changes in the proportion of CD25 CD3 PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type
SIVmacJ5 on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5 on
day 218. (C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal
reference range based on 2 standard deviations  mean proportion of CD25 CD3 PBMC derived from two prebleeds of each animal used in this
study.
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stimulation before or after SIV challenge (data not
shown). Following challenge of group A with SIVmacJ5
and group B with SIVmacC8 the proportion of IFN-
lymphocytes (Figs. 7A and 7B) peaked significantly
above reference range at day 113 by paired t test (P 
0.011 and P  0.046, respectively). At day 113 the mean
proportion of IFN- lymphocytes from group A was
nonsignificantly greater than that from group B. No sig-
nificant increase in the proportion of group B IFN-
lymphocytes was detected following rechallenge with
FIG. 5. Changes in the proportion of FAS CD8 PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type
SIVmacJ5 on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5 on
day 218. (C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal
reference range based on 2 standard deviations  mean proportion of FAS CD8 PBMC derived from two prebleeds of each animal used in this
study.
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SIVmacJ5. In contrast, contemporaneous challenge of
group C with SIVmacJ5 resulted in a significant increase
in the proportion of IFN- lymphocytes (Fig. 7C) above
reference range at day 246, by paired t test (P  0.047).
Following challenge of group A with SIVmacJ5 and
group B with SIVmacC8, the proportion of IL-2 lympho-
cytes (Figs. 8A and 8B) decreased significantly below
reference range at day 29, by paired t test (P  0.010
and P  0.002, respectively). Thereafter, levels of IL-2
lymphocytes in SIVmacJ5 animals remained significantly
below reference range except on days 85 and 246. In
contrast, levels of IL-2 lymphocytes in SIVmacC8 ani-
FIG. 6. Changes in the proportion of CD3 IL-4 PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type
SIVmacJ5 on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5 on
day 218. (C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal
reference range based on 2 standard deviations  mean proportion of IL-4 CD3 PBMC derived from two prebleeds of each animal used in this
study.
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mals remained within reference range except on day 218.
No significant decrease in the proportion of group B
IL-2 lymphocytes was detected following rechallenge
with SIVmacJ5. Contemporaneous challenge of group C
with SIVmacJ5 resulted in a significant decrease in the
proportion of IL-2 lymphocytes (Fig. 8C) to below refer-
ence range at day 308, by paired t test (P  0.009).
DISCUSSION
This work builds upon our previous observations that
protection conferred by live attenuated SIV cannot be
transferred with immune serum (Almond et al., 1997) and
cannot be abrogated by depletion of cytotoxic T-cells
(Stebbings et al., 1998). The aim of this investigation was
FIG. 7. Changes in the proportion of IFN- PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type SIVmacJ5
on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5 on day 218.
(C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal reference range
based on 2 standard deviations  mean proportion of IFN PBMC derived from two prebleeds of each animal used in this study.
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to address the role of secondary cellular immune re-
sponses in the potent protection against superinfection
conferred by vaccination with live attenuated SIV. This
study clearly demonstrates that primary infection with
both wild-type and attenuated SIV strongly stimulates
host cellular immune responses. Although attenuated
SIV viral loads were 100-fold lower than wild-type SIV,
both challenges elicited a significant increase in the
numbers of activated T-cells, CD8 lymphocytes, and
cells positive for IFN- or IL-4 by intracellular cytokine
staining. In addition, both attenuated and wild-type SIV
challenges resulted in profound loss of cells positive for
FIG. 8. Changes in the proportion of IL-2 PBMC following SIV challenge. (A) Macaques R33–R36 (group A) challenged with wild-type SIVmacJ5
on day 0. (B) Macaques R37–R40 (group B) challenged with attenuated SIVmacC8 on day 0 and rechallenged with wild-type SIVmacJ5 on day 218.
(C) Macaques R265–R268 (group C) challenged with wild-type SIVmacJ5 on day 218. Upper and lower dashed lines delineate normal reference range
based on 2 standard deviations  mean proportion of IL-2 PBMC derived from two prebleeds of each animal used in this study.
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IL-2 by intracellular cytokine staining in the absence of
significant CD4 lymphocyte loss.
The importance of active cellular immune responses
in controlling initial levels of SIV and simian–human
immunodeficiency virus replication in macaques has
been demonstrated in lymphocyte depletion experiments
(Jin et al., 1999; Matano et al., 1998; Schmitz et al., 1999).
However, similar experiments have failed to identify a
role for cellular immunity in mediating the protection
conferred by live attenuated SIV vaccines (Stebbings et
al., 1998). Recall of cell-mediated immunity is character-
ized by massive proliferation of antigen-specific T-cells
(Flynn et al., 1999) and expression of activation markers
such as CD25 and HLA-DR by responding T-cells
(Mardiney et al., 1996; Neal and Splitter, 1998). If recall of
a vigorous cellular immune response to infection is the
mechanism of protection conferred by live attenuated
SIV vaccines, then rechallenge with wild-type SIV should
evoke recall of such responses. In this study macaques
vaccinated with attenuated SIVmacC8 showed no evi-
dence of superinfection with wild-type SIVmacJ5 by virol-
ogy, serology, or molecular diagnostic assays. Yet, there
was no evidence for reactivation of T-cells, increased
numbers of CD8 PBMC, perturbed IL-4, IL-2, or IFN-
cytokine profiles following challenge.
The observed alterations in cytokine and T-cell activa-
tion in the SIV model are similar to those reported by
others (Estaquier et al., 2000; Smit-McBride et al., 1998;
Spring et al., 1997; Xiong et al., 2001). The greater in-
crease in the proportion of IL-4 and IFN- cells ob-
served with wild-type SIVmacJ5 versus the nef deleted
SIVmacC8 challenge mirrors anti-SIV antibody re-
sponses and probably reflects a stronger immune re-
sponse to the greater size and duration of the SIVmacJ5
primary viremia. However, as a significant peak in the
proportion of IFN- cells was observed only at a single
time point, this result should be interpreted with caution.
Nevertheless, an increased capacity for IFN- secretion
in the SIV model is in agreement with the findings of
others (Smit-McBride et al., 1998). The reduced numbers
of CD3 IL-4 cells observed following mitogen stimula-
tion may be linked to the activity of IFN- to limit IL-4
secretion (Marcinkiewicz and Chain, 1993). Most studies
of IL-4 secretion in patients following HIV infection have
reported increased levels (Barcellini et al., 1994; Clerici
et al., 1996; Klein et al., 1997; Meroni et al., 1996) although
others have reported no change (Fan et al., 1993;
Meyaard et al., 1996). The absence of a significant in-
crease in CD3 IL-4 cells following SIVmacC8 chal-
lenge in macaques R39 and R40 may indicate a less
vigorous humoral response in these animals or that the
peak increase was missed. It was noted that, within the
SIVmacC8 group, detection of neutralizing antibodies
was delayed in both R39 and R40. No clear consensus
exists over changes in IFN- secretory capacity follow-
ing HIV-1 infection with contradictory reports describing
both increased (Caruso et al., 1995; Fan et al., 1993;
Westby et al., 1998) and decreased levels (Hagiwara et
al., 1996; Clerici et al., 1996; Meroni et al., 1996; Meyaard
et al., 1996) in patients. These disparate observations
may be related to the stage of disease progression, AIDS
being associated with general failure to secrete cyto-
kines, or technical issues such as the type of mitogen
used to stimulate PBMC. Stimulation with phytohemag-
glutinin (PHA) was used when decreases in the potential
IFN- secretion were reported (Clerici et al., 1996;
Meroni et al., 1996), whereas phorbol 12-myristate 13-
acetate (PMA)  ionomycin was employed in studies
where increases in IFN- secretion were observed (Ca-
ruso et al., 1995; Westby et al., 1998). Production of IFN-
by antigen-stimulated T-cells requires the presence of
IL-2 during both the priming and the expression phases.
In contrast, production of IL-4 requires IL-2 only during
the priming phase (Billiau, 1996). Observations of defects
in IFN- but not IL-4 production during HIV-1 (Barcellini
et al., 1994; Klein et al., 1997) infection may therefore be
related to the paucity of IL-2 production. In the SIV model
a defect in the ability of antigen-specific CD8 lympho-
cytes to produce IFN- is restored by IL-2 treatment
(Xiong et al., 2001).
Infection with wild-type SIVmacJ5 and attenuated SIV-
macC8 resulted in equivalent depletion of IL-2 lympho-
cytes 4 weeks postchallenge. However, between weeks
7 and 16, levels of IL-2 lymphocytes returned to refer-
ence range in all SIVmacC8-infected animals but only in
two SIVmacJ5 animals. On an individual animal basis
infection with wild-type SIVmacJ5 produced a sustained
suppression of IL-2 cells in two of four macaques. Loss
of IL-2 lymphocytes in both SIVmacC8 and SIVmacJ5
animals was again observed between weeks 18 and 31.
It is unlikely that an increase in IL-2 lymphocytes at
week 33 in SIVmacC8 animals is related to the SIVmacJ5
rechallenge as a similar increase was observed at this
time in the two SIVmacJ5-infected animals which were
not rechallenged. Observed decreases in IL-2 secretion
following antigen or mitogen stimulation of PBMC from
HIV-infected patients (Clerici et al., 1996; Meroni et al.,
1996; Meyaard et al., 1996; Westby et al., 1998) or SIV-
infected macaques (Koopman et al., 2001; Spring et al.,
1997) are widely accepted. Although mitogen stimulation
is not antigen specific it does reflect changes in memory
cell subsets, with polarized cytokine expression, that
would otherwise not be observed when looking at gross
lymphocyte populations (Koopman et al., 2001). These
changes can be either immune-mediated expansion of
memory subsets or immunopathogenic depletion. After
week 2, the peak of primary viremia, less than 10 cells for
SIVmacC8 and 100 cells for SIVmacJ5 challenged ani-
mals per 1  106 PBMC are infected. By 8 weeks postin-
fection loads are normally 20- to 100-fold lower. There-
fore, it is unlikely that perturbations of cytokine and
activation marker expression observed here are due to a
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direct effect of SIV genes on host cells as less than 1% of
lymphocytes are infected. As all of these animals were
cohoused together in a contained facility, it is doubtful
that nonspecific factors such as other viral illnesses
could have affected only one group of animals and per-
turbed their cytokine profiles. Analysis of lymph node
cells may have revealed changes in activation marker
and cytokine expression earlier. However, as lympho-
cytes from lymph nodes traffic through the peripheral
blood, changes in these lymphoid compartments are
generally reflected in PBMC.
Increased FAS expression has previously been re-
ported for the CD8 fraction of PBMC in HIV-1-infected
patients (Gehri et al., 1996; Sloand et al., 1997) and
SIV-infected macaques (Iida et al., 1999; Xu et al., 1997).
Increased FAS expression is a marker of T-cell activation
(Tucek-Szabo et al., 1996) regulated by increased IFN-
secretion (Novelli et al., 1996). Higher numbers of FAS
CD8 lymphocytes following SIVmacJ5 than SIVmacC8
challenge may reflect greater IFN- secretion and ex-
pansion of memory cell subsets. Alternatively, increased
FAS expression by CD8 lymphocytes of SIVmacJ5 ani-
mals may be due to chronic activation in the absence of
IL-2, inducing a state of anergy and susceptibility to
apoptosis.
Although the second SIVmacJ5 challenge used was
half the TCID50 value of the first this was still sufficient
to infect all four controls and induce CD4 cell loss in
R268. No significant differences between the two SIV-
macJ5 challenges in terms of peak viremia, serology,
and expression of T-cell activation markers were ob-
served. However, it is interesting that differences in
the kinetics of cytokine responses of these two non-
contemporaneous SIVmacJ5 challenges were noted.
Since C8166 cells used here for virus reisolation
poorly express the major SIV coreceptor CCR5, virus
reisolation results may not accurately reflect cell-as-
sociated viral loads.
While there are some who believe that it is very
difficult to elicit protection against immunodeficiency
virus by vaccination, no evidence for superinfection
was found here. A molecular assay has been devel-
oped that differentiates the closely related vaccine
and rechallenge viruses. This is capable of detecting
even a single copy of SIVmacC8 or SIVmacJ5 (Rose et
al., 1995) yet did not detect superinfection. More im-
pressive perhaps is the failure to detect an anamnes-
tic antibody response. Anamnestic antibody re-
sponses have previously been reported following su-
perinfection of attenuated SIV vaccinees (Norley et al.,
1996). However, despite the marked protection ob-
served here we could not rule out the presence of
minor species of viral sequences in the presence of
other SIV-related sequences. The lack of a detectable
systemic secondary immune response may mean that
the vaccine protection obtained was mediated through
local immune responses. It has been reported that
virus-specific CD8 lymphocytes induced by attenu-
ated SIV immunization express the mucosa-homing
receptor 47 and home to the intestinal mucosa
(Cromwell et al., 2000). However, 47 is expressed
by a subset of virus-specific CD8 cells, initially ex-
posed to antigen at gastrointestinal sites, that are
readily detectable trafficking in the periphery. Conse-
quently, activation of even local immune responses
would be reflected in the periphery during subsequent
trafficking.
Failure to detect recall of active cellular immune re-
sponses to rechallenge may also be explained by lack of
productive infection. It is possible that resistance to
rechallenge does not elicit a strong systemic immune
response because the level of immunity against the
established attenuated virus is sufficient. Nevertheless,
strong depletion of cellular immune responses in SIV-
macC8-infected macaques by Campath-1H, a treatment
developed to prevent transplant rejection, is unable to
abrogate protection against a SIVmacJ5 challenge (Steb-
bings et al., 1998). Furthermore, cytotoxic T cell re-
sponses in animals immunized with attenuated SIV do
not correlate with protection against pathogenic SIV in-
fection (Nixon et al., 2000). Superinfection resistance
could be explained if it were mediated by neutralizing
antibody responses that prevented initial infection. Yet, it
has been demonstrated that passive transfer of immune
sera from attenuated SIV-infected macaques confers no
protective capacity upon naive recipients (Almond et al.,
1997). Even when superinfection does occur and is effi-
ciently controlled, this occurs in the absence of detect-
able secondary cellular immune responses (Khatissian
et al., 2001).
Another possibility is that nonimmune mechanisms of
protection such as retroviral interference (Corbin and
Sitbon, 1993; Corbin et al., 1994) or depletion of a critical
target cell population (Mattapallil et al., 1998) may have a
role to play. It has been reported that receptor interfer-
ence is unlikely to be a mechanism of protection in
attenuated SIV-immunized animals since they are pro-
tected against superinfection with an attenuated SIV
pseudotype carrying the amphotropic envelope of mu-
rine leukemia virus (Gundlach et al., 1998) that uses Pit2
and not CD4 as a receptor. However, the authors base
their conclusions on the lack of virus reisolation, anam-
nestic immune response, and lack of seroconversion to
SIV-MLV envelope. Yet, a previous wild-type SIVmac239
superinfection of the same animals did not increase
antibody titers or result in increased virus reisolation
after challenge. Finally, the authors concede in their
conclusions that in agreement with their own PCR data
low-level SIV-MLV replication did occur in the vaccinees.
In conclusion, our findings indicate that potent vaccine
protection conferred by live attenuated virus can occur in
the absence of an active systemic secondary cellular
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immune response. Further carefully developed experi-
ments are required to address more directly the ability of
live attenuated virus vaccines to elicit protection in the
absence of a systemic secondary cellular immune re-
sponse.
MATERIALS AND METHODS
Animals and virus
Twelve juvenile male or female purpose-bred cyno-
molgus macaques (Macaca fascicularis) were used in
this study. Macaques were screened by virus isolation
and serology and shown to be free from infection by SIV
or simian D-type retroviruses prior to entry into this study.
Macaques were housed and maintained in accordance
with Home Office Guidelines for the care and mainte-
nance of nonhuman primates. All animals were sedated
with ketamine before challenge or venipuncture and
were examined clinically while under anesthesia.
The SIVmac32H (pC8) virus clone differs from the
SIVmac32H (pJ5) clone by a 12-bp deletion and two
nonsynonymous nucleotide changes resulting in conser-
vative amino acid changes in the nef open reading frame
(Rud et al., 1994a). Virus stocks termed SIVmacJ5 and
SIVmacC8 were prepared as follows. Cultured PBMC
from cynomolgus macaque L156 stimulated with phyto-
hemagglutinin (ICN Pharmaceuticals, Ltd., Basing-stoke,
Hampshire UK) and recombinant human IL-2 (NIBSC,
Potters Bar, Hertfordshire, UK) were infected with either
the 9/90 pool of SIVmacC8 or the 9/90 pool of SIVmacJ5
(Cranage et al., 1997). Cell-free supernatants harvested
on day 14 were used to infect spleen cells from L156
stimulated with phytohemagglutinin and recombinant hu-
man IL-2. Cultures were harvested on day 11 and the
cell-free supernatants were aliquoted and stored (Sil-
vera, 1997). On day 0 macaques R33 through R36 were
inoculated intravenously with 750 TCID50 of SIVmacJ5 in
parallel with macaques R37 through R40, which received
750 TCID50 of SIVmacC8. On day 218 R37 through R40
and four naive controls, R265 through R268, were chal-
lenged with 375 TCID50 of SIVmacJ5.
Virus detection
Amplification of SIV gag sequences in genomic DNA
from macaque PBMC was performed using a PCR-based
assay, employing two rounds of amplification with nested
primer pairs as previously described (Rose et al., 1995).
In order to differentiate between the two SIV clones, a
diagnostic amplification of a region of the nef gene en-
compassing the 12-bp deletion of SIVmacC8 was em-
ployed. The PCR product derived from SIVmacC8 and
SIVmacJ5 was distinguished by differential digestion
with restriction enzyme RsaI and the product was re-
solved by gel electrophoresis, as described previously
(Rose et al., 1995). Proviral DNA loads per 106 PBMC
were determined by an end-point dilution method, as
previously described (Almond et al., 1999; Slade et al.,
1995).
Plasma viral RNA (vRNA) levels were determined 15
days postinfection from EDTA-treated plasma using a
modified RT-PCR assay, based on a previously described
method (Berry et al., 1998), with Titan reagents (Roche
Diagnostics, Lewes, UK). The amount of specific PCR
product was quantified by hybridization with an alkaline
phosphatase-coupled probe using chemiluminescence
in a microtiter-based assay. The sensitivity of the assay
is 2.3 log SIV RNA copies per milliliter.
Virus reisolation from separated PBMC was deter-
mined by coculture with C8166 cells, as previously de-
scribed (Stebbings et al., 1998). Either when syncytia
were observed or after 28 days the presence of replicat-
ing SIV was confirmed in an antigen capture assay, as
previously described (Rose et al., 1995).
Antibody detection
Titers of binding antibodies to SIV envelope gp140
(RepliGen Corp., Needham, MA) or lacZ-p27 (Almond et
al., 1990) were determined from heat-inactivated (56°C
for 1 h) plasma samples by ELISA (Silvera et al., 1994;
Stott et al., 1990). Neutralizing antibody end-point titers
were taken as the dilution of serum in the serum–virus
mixture inhibiting p27 antigen production by at least 75%,
expressed as log10 of the reciprocal of the end-point
dilution (Kent et al., 1994).
Flow cytometry
Anti-human monoclonal antibodies previously identi-
fied to cross-react with macaque PBMC and cytokines
were used in this study. For surface staining 200 l of
whole blood was incubated at 4°C for 30 min with the
following antibody pairs in parallel: CD4-FITC (OKT4,
Ortho-Clinical Diagnostics, Amersham, Buckingham-
shire, UK) and CD8-PE (Leu-2a, Becton Dickinson, Ox-
ford, UK); monkey CD3-FITC (FN18, Serotec, Oxford, UK)
and CD25-PE (M-A251, Pharmingen, San Diego, CA);
monkey CD3-FITC and HLA-DR-PE (Tu36, Pharmingen);
CD4-FITC and CD95-PE (DX2, Pharmingen); and CD8-
FITC and CD95-PE. Red blood cells were removed using
FACS lysing solution (Becton Dickinson).
For intracellular cytokine staining, PBMC isolated on a
Percoll gradient (Amersham Pharmacia Biotech, Upp-
sala, Sweden) were resuspended at 2  106/ml in RPMI
1640 medium supplemented with 10% FCS, 50 IU/ml
penicillin–streptomycin (Gibco BRL, Paisley, Scotland)
and 2 M/ml monensin (Sigma–Aldrich Co. Ltd., Dorset,
UK). Cultures were incubated overnight at 37°C in 24-
well plates with and without mitogen, 10 ng/ml of PMA
1 g/ml ionomycin (Sigma–Aldrich Co. Ltd.), washed
once in PBS, fixed at room temperature in Permeafix
(Ortho Diagnostic Systems Inc.) for 30 min; washed once
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with PBS containing 4% FCS  0.05% sodium azide, and
incubated for 90 min at 4°C with the following antibody
pairs in parallel: anti-IL-2 RPE conjugate (MQ1-17H12,
Pharmingen) plus anti-IFN- FITC conjugate (4S.B3,
Pharmingen) and anti-IL-4 RPE conjugate (8D4-8, Pharm-
ingen) plus anti-monkey CD3 FITC conjugate. Following
staining, PBMC were washed twice with PBS containing
4% FCS  0.05% sodium azide and resuspended in 2%
paraformaldehyde. Additional staining with appropriate
isotype controls (Serotec) was used to confirm specificity
of labeling. Acquisition of 10,000 events was carried out
using a FACScan cytometer and analyzed using Lysis II
software.
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